drugset / Trial / NCT04056468
A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function
Non-randomizedParallel-groupOpen-labelOther
Summary
The purpose of this study is to characterize the single-dose plasma PK of mobocertinib and its active metabolites (AP32960 and AP32914) in participants with moderate and/or severe HI compared to matched-healthy participants with normal hepatic function.
Timeline
- Start
- 2020-10-09
- Primary completion
- 2022-02-05
- Completion
- 2022-02-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mobocertinib | Small molecule | 40 mg | Oral |
Indications
No indication recorded.